Nektar Therapeutics (NKTR)

In June 2025, positive results from the Phase 2b REZOLVE-AD study of rezpegaldesleukin led to a substantial increase in NKTR's stock price. In July 2025, Nektar closed an underwritten public offering of $115 million of its common stock. In November 2025, Nektar reported its Q3 2025 financial results, received FDA Fast Track designation for rezpegaldesleukin, presented new data from the REZOLVE-AD Phase 2b study at the ACAAI 2025 Annual Scientific Meeting, and Citi initiated coverage on Nektar with a "Buy" rating. Between November 25, 2024, and November 21, 2025, the share price increased by 231.99%. Over the last year, Nektar Therapeutics has shown a 298.12% increase in stock price. Nektar Therapeutics insiders have sold more company stock than they have bought in the past three months.

Nektar Therapeutics' demand is not subject to typical seasonality. Instead, investor interest is driven by milestones in its research and development pipeline, such as clinical trial results, regulatory approvals, and strategic partnerships. Stock returns may show seasonality due to market trading patterns.

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative medicines, particularly in immunotherapy. Founded in 1990 and based in San Francisco, California, Nektar uses its technologies to improve drug characteristics. The company's pipeline includes Rezpegaldesleukin (REZPEG, or NKTR-358) for atopic dermatitis and alopecia areata, NKTR-255 to boost the immune system's ability to fight cancer, and preclinical programs like TNFR2 antibody, bispecific programs (NKTR-0165 and NKTR-0166), and a modified hematopoietic colony stimulating factor (CSF) protein (NKTR-422). Nektar has previously developed Exubera and Movantik. The company generates revenue through collaborations, partnerships, and licensing agreements.

Nektar Therapeutics is headquartered in San Francisco, California, with operational facilities in Huntsville, Alabama, and Hyderabad, India. The company has employees across six continents, including North America, Asia, and Europe, indicating a global reach.

Nektar Therapeutics' brand reputation has been positively influenced by successful Phase 2b results for rezpegaldesleukin in atopic dermatitis and the FDA Fast Track designation for rezpegaldesleukin in severe alopecia areata. Presentation of promising data at scientific meetings also contributes positively. Analyst sentiment has a "Moderate Buy" consensus.

Nektar Therapeutics' ownership is primarily held by institutional investors, with significant holdings by BVF Inc/il, Vanguard Group Inc, Morgan Stanley, and BlackRock, Inc. Insiders hold a smaller percentage, with Deep Track Capital LP noted as the largest individual shareholder. Retail investors also hold a notable portion of the company's stock.